| 446 Publications |
This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.
Export
-
1.
2012A. Eden Evins; Alan I. Green; John M. Kane; Robin M. Murray
The effect of marijuana use on the risk for schizophrenia
Journal of Clinical Psychiatry. 2012;73(11):1463-1468.0 -
2.
2012Peter Manu; Muhammad Asif; Sameer Khan; Husnein Ashraf; Anup Mani; Perihan Guvenek-Cokol; Hanna Lee; John M. Kane; Christoph U. Correll
Comprehensive Psychiatry. 2012;53(7):968-974.0 -
3.
2012Anil K. Malhotra; Christoph U. Correll; Nabilah I. Chowdhury; Daniel J. Müller; Peter K. Gregersen; Annette T. Lee; Arun K. Tiwari; John M. Kane; W. Wolfgang Fleischhacker; Rene S. Kahn; et al.
Archives of General Psychiatry. 2012;69(9):904-912.6 -
4.
2012Jian-Ping Zhang; Jeffrey J. Weiss; Melissa McCardle; Hope Klopchin; Eileen Rosendahl; Lawrence Maayan; Antonio Convit; John M. Kane; Peter Manu; Christoph U. Correll
Journal of Clinical Psychopharmacology. 2012;32(4):458-464.2 -
5.
2012Larry Alphs; Fabrizio Benedetti; W. Wolfgang Fleischhacker; John M. Kane
International Journal of Neuropsychopharmacology. 2012;15(7):1003-1014.4 -
6.
2012Juan A. Gallego; Jimmi Nielsen; Marc De Hert; John M. Kane; Christoph U. Correll
Safety and tolerability of antipsychotic polypharmacy
Expert Opinion on Drug Safety. 2012;11(4):527-542.5 -
7.
2012Taro Kishi; Yasuhisa Fukuo; Tomo Okochi; Kunihiro Kawashima; Masatsugu Moriwaki; Osamu Furukawa; Kiyoshi Fujita; Giovanna M. Musso; Christoph U. Correll; John M. Kane; et al.
NeuroMolecular Medicine. 2012;14(2):131-138.1 -
8.
2012Juan A. Gallego; John Bonetti; Jianping Zhang; John M. Kane
Schizophrenia Research. 2012;138(1):18-28.7 -
9.
2012John M. Kane; Raymond Sanchez; Pamela P. Perry; Na Jin; Brian R. Johnson; Robert A. Forbes; Robert D. McQuade; William H. Carson; W. Wolfgang Fleischhacker
Journal of Clinical Psychiatry. 2012;73(5):617-624.2 -
10.
2012Philip R. Szeszko; Katherine L. Narr; Owen R. Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M. Kane; Robert M. Bilder; Delbert G. Robinson
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia
Schizophrenia Bulletin. 2012;38(3):569-578.1 -
11.
2012John M. Kane; Lauren D. Hill; Bruce J. Kinon; William Z. Potter; Mark H. Rapaport; Nina R. Schooler
Journal of Clinical Psychiatry. 2012;73(4):504-505.0 -
12.
2012John M. Kane; Ronghua Yang; James M. Youakim
Schizophrenia Research. 2012;135(1-3):116-122.0 -
13.
2012John M Kane
Addressing nonresponse in schizophrenia.
The Journal of clinical psychiatry. 2012;73(2):e07.0 -
14.
2012Peter Manu; Deepak Sarpal; Owen Muir; John M. Kane; Christoph U. Correll
Schizophrenia Research. 2012;134(2-3):180-186.7 -
15.
2012Saurav Guha; Jeffrey A. Rosenfeld; Anil K. Malhotra; Annette T. Lee; Peter K. Gregersen; John M. Kane; Itsik Pe'er; Ariel Darvasi; Todd Lencz
Implications for health and disease in the genetic signature of the Ashkenazi Jewish population
Genome Biology. 2012;13(1).4 -
16.
2012Taro Kishi; Yasuhisa Fukuo; Tomo Okochi; Kunihiro Kawashima; Tsuyoshi Kitajima; Toshiya Inada; Norio Ozaki; Giovanna M. Musso; John M. Kane; Christoph U. Correll; et al.
Serotonin 6 receptor gene and schizophrenia: Case-control study and meta-analysis
Human Psychopharmacology. 2012;27(1):63-69.0 -
17.
2012A. John Camm; Onur N. Karayal; Herbert Meltzer; Sheela Kolluri; Cedric O'Gorman; Jeffrey Miceli; Thomas Tensfeldt; John M. Kane
Ziprasidone and the corrected QT interval: A comprehensive summary of clinical data
CNS Drugs. 2012;26(4):351-365.1 -
18.
2012John M Kane
Assessing and measuring nonresponse in schizophrenia.
The Journal of clinical psychiatry. 2012;73(1):e04.0 -
19.
2012John M. Kane; Barbara Cornblatt; Christoph U. Correll; Terry Goldberg; Todd Lencz; Anil K. Malhotra; Delbert Robinson; Philip Szeszko
The field of schizophrenia: Strengths, weaknesses, opportunities, and threats
Schizophrenia Bulletin. 2012;38(1):1-4.0 -
20.
2011Christoph U. Correll; Taishiro Kishimoto; Jimmi Nielsen; John M. Kane
Quantifying Clinical Relevance in the Treatment of Schizophrenia
Clinical Therapeutics. 2011;33(12):B16-B39.4 -
21.
2011Juan A. Gallego; Delbert G. Robinson; Serge M. Sevy; Barbara Napolitano; Joanne McCormack; Martin L. Lesser; John M. Kane
Journal of Clinical Psychiatry. 2011;72(12):1691-1696.4 -
22.
2011John M Kane; Christoph U Correll
Performance improvement CME: managing schizophrenia.
The Journal of clinical psychiatry. 2011;72(10):e31.0 -
23.
2011John M Kane
Improving treatment adherence in patients with schizophrenia.
The Journal of clinical psychiatry. 2011;72(9):e28.3 -
24.
2011Christoph U. Correll; John M. Kane; Peter Manu
Obesity and coronary risk in patients treated with second-generation antipsychotics
European Archives of Psychiatry and Clinical Neuroscience. 2011;261(6):417-423.10 -
25.
2011Christoph U. Correll; Ladan Shaikh; Juan A. Gallego; Jeffrey Nachbar; Vladimir Olshanskiy; Taishiro Kishimoto; John M. Kane
Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Schizophrenia Research. 2011;131(1-3):58-62.7 -
26.
2011Serge Sevy; Delbert G. Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Psychiatry Research. 2011;188(3):310-314.4 -
27.
2011Christoph U. Correll; Jennifer Harris; Vicki Figen; John M. Kane; Peter Manu
Journal of Child and Adolescent Psychopharmacology. 2011;21(4):365-368.2 -
28.
2011John M Kane
Performance improvement CME: schizoaffective disorder.
The Journal of clinical psychiatry. 2011;72(7):e23.0 -
29.
2011Peter Manu; John M. Kane; Christoph U. Correll
Sudden deaths in psychiatric patients
Journal of Clinical Psychiatry. 2011;72(7):936-941.6 -
30.
2011Margaret G. Woerner; Christoph U. Correll; Jose Ma J. Alvir; Blaine Greenwald; Howard Delman; John M. Kane
Neuropsychopharmacology. 2011;36(8):1738-1746.1 -
31.
2011Cedric O'Gorman; Shitij Kapur; Sheela Kolluri; John Kane
Human Psychopharmacology. 2011;26(4-5):282-290.2 -
32.
2011Christoph U. Correll; Johnny D. Lops; Vicki Figen; Anil K. Malhotra; John M. Kane; Peter Manu
QT interval duration and dispersion in children and adolescents treated with ziprasidone
Journal of Clinical Psychiatry. 2011;72(6):854-860.3 -
33.
20113 -
34.
2011Virginia L. Stauffer; Michael Case; Bruce J. Kinon; Robert Conley; Haya Ascher-Svanum; Sara Kollack-Walker; John Kane; Joseph McEvoy; Jeffrey Lieberman
Psychiatry Research. 2011;187(1-2):42-48.7 -
35.
2011Maria C. Athanasiou; Michael Dettling; Ingolf Cascorbi; Igor Mosyagin; Benjamin A. Salisbury; Kerri A. Pierz; Wei Zou; Heidi Whalen; Anil K. Malhotra; Todd Lencz; et al.
Journal of Clinical Psychiatry. 2011;72(4):458-463.19 -
36.
2011Claudia Leucht; Stephan Heres; John M. Kane; Werner Kissling; John M. Davis; Stefan Leucht
Schizophrenia Research. 2011;127(1-3):83-92.60 -
37.
2011John M. Kane; Mary Mackle; Linda Snow-Adami; Jun Zhao; Armin Szegedi; John Panagides
Journal of Clinical Psychiatry. 2011;72(3):349-355.13 -
38.
2011John M Kane
Transitioning from acute to long-term treatment in schizophrenia.
The Journal of clinical psychiatry. 2011;72(3):e10.0 -
39.
2011Stephen J. Ruberg; Lei Chen; Virginia Stauffer; Haya Ascher-Svanum; Sara Kollack-Walker; Robert R. Conley; John Kane; Bruce J. Kinon
BMC Psychiatry. 2011;11.3 -
40.
2011John M. Kane; Steven G. Potkin; David G. Daniel; Peter F. Buckley
Journal of Clinical Psychiatry. 2011;72(2):194-204.5 -
41.
2011Brian L. Strom; Sybil M. Eng; Gerald Faich; Robert F. Reynolds; Ralph B. D'Agostino; Ruskin Jeremy; John M. Kane
American Journal of Psychiatry. 2011;168(2):193-201.26 -
42.
2011John M Kane
Addressing side effects from antipsychotic treatment in schizophrenia.
The Journal of clinical psychiatry. 2011;72(2):e07.2 -
43.
2011John M. Kane
Lurasidone: A clinical overview
Journal of Clinical Psychiatry. 2011;72(SUPPL. 1):24-28.9 -
44.
2011John M. Kane
Recent advances in treatments for schizophrenia
Journal of Clinical Psychiatry. 2011;72(SUPPL. 1):3.0 -
45.
2011Haya Ascher-Svanum; Michael D. Stensland; Xiaomei Peng; Douglas E. Faries; Virginia L. Stauffer; Olawale O. Osuntokun; John M. Kane
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
Current Medical Research and Opinion. 2011;27(1):115-122.3 -
46.
2010John M Kane
The differential diagnosis of schizoaffective disorder.
The Journal of clinical psychiatry. 2010;71(12):e33.0 -
47.
2010John M. Kane; Deepak C. D'Souza; Ashwin A. Patkar; James M. Youakim; Jane M. Tiller; Ronghua Yang; Richard S. E. Keefe
Journal of Clinical Psychiatry. 2010;71(11):1475-1481.14 -
48.
2010Todd Lencz; Delbert G. Robinson; Barbara Napolitano; Serge Sevy; John M. Kane; David Goldman; Anil K. Malhotra
Pharmacogenetics and Genomics. 2010;20(9):569-572.18 -
49.
2010John M. Kane; Christoph U. Correll
Past and present progress in the pharmacologic treatment of schizophrenia
Journal of Clinical Psychiatry. 2010;71(9):1115-1124.46 -
50.
2010John M Kane; Thomas Re Barnes; Christoph U Correll; Gary Sachs; Peter Buckley; James Eudicone; Robert McQuade; Quynh-Van Tran; Andrei Pikalov III; Sheila Assunção-Talbott
Journal of Psychopharmacology. 2010;24(7):1019-1029.14 -
51.
2010Serge Sevy; Delbert G. Robinson; Barbara Napolitano; Raman C. Patel; Handan Gunduz-Bruce; Rachel Miller; Joanne McCormack; Beth S Lorell; John Kane
Schizophrenia Research. 2010;120(1-3):101-107.13 -
52.
2010Bruce J. Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L. Stauffer; Sara Kollack-Walker; Wei Zhou; Shitij Kapur; John M. Kane; Dieter Naber
Schizophrenia Research. 2010;118(1-3):176-182.9 -
53.
2010Katherine E. Burdick; Pamela DeRosse; John M. Kane; Todd Lencz; Anil K. Malhotra
American Journal of Psychiatry. 2010;167(4):436-443.15 -
54.
2010John M. Kane; Michael Cohen; Jun Zhao; Larry Alphs; John Panagides
Journal of Clinical Psychopharmacology. 2010;30(2):106-115.38 -
55.
20101 -
56.
2010John M. Kane; Holland C. Detke; Dieter Naber; Gopalan Sethuraman; Daniel Y. Lin; Richard F. Bergstrom; David McDonnell
American Journal of Psychiatry. 2010;167(2):181-189.43 -
57.
2010Bruce J. Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L. Stauffer; Sara Kollack-Walker; Wei Zhou; Shitij Kapur; John M. Kane
Neuropsychopharmacology. 2010;35(2):581-590.49 -
58.
2010John M. Kane; Christoph U. Correll
Pharmacologic treatment of schizophrenia
Dialogues in Clinical Neuroscience. 2010;12(3):345-357.12 -
59.
2010John M. Kane
Strategies for making an accurate differential diagnosis of schizoaffective disorder
Journal of Clinical Psychiatry. 2010;71(SUPPL. 2):4-7.2 -
60.
2009Lars Helldin; John M. Kane; Fredrik Hjärthag; Torsten Norlander
Schizophrenia Research. 2009;115(1):67-73.6 -
61.
2009Julie B. Penzner; Melissa Dudas; Ema Saito; Vladimir Olshanskiy; Umesh H. Parikh; Sandeep Kapoor; Raja Chekuri; Dominick Gadaleta; Jennifer Avedon; Eva M. Sheridan; et al.
Journal of Child and Adolescent Psychopharmacology. 2009;19(5):563-573.11 -
62.
2009John M. Kane; Christoph U. Correll; Donald C. Goff; Brian Kirkpatrick; Stephen R. Marder; Estelle Vester-Blokland; Wei Sun; William H. Carson; Andrei Pikalov; Sheila Assunção-Talbott
Journal of Clinical Psychiatry. 2009;70(10):1348-1357.39 -
63.
2009John M. Kane; Wolfgang W. Fleischhacker; Lars Hansen; Roy Perlis; Andrei Pikalov III; Sheila Assunção-Talbott
Akathisia: An updated review focusing on second-generation antipsychotics
Journal of Clinical Psychiatry. 2009;70(5):627-643.34 -
64.
2009Christoph U. Correll; Christine Rummel-Kluge; Caroline Corves; John M. Kane; Stefan Leucht
Schizophrenia Bulletin. 2009;35(2):443-457.101 -
65.
2009John M. Kane; Olawale Osuntokun; Ludmila A. Kryzhanovskaya; Wen Xu; Virginia L. Stauffer; Susan B. Watson; Alan Breier
Journal of Clinical Psychiatry. 2009;70(4):572-581.24 -
66.
2009Todd Lencz; Robert H. Lipsky; Pamela DeRosse; Katherine E. Burdick; John M. Kane; Anil K. Malhotra
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes
British Journal of Psychiatry. 2009;194(4):313-318.18 -
67.
2009Daniel E. Casey; David G. Daniel; Carol Tamminga; John M. Kane; Tram Tran-Johnson; Patricia Wozniak; Walid Abi-Saab; Jeff Baker; Laura Redden; Nicholas Greco; et al.
Neuropsychopharmacology. 2009;34(5):1330-1338.19 -
68.
2009Terry E. Goldberg; Katherine E. Burdick; Joanne McCormack; Barbara Napolitano; Raman C. Patel; Serge M. Sevy; Robert Goldman; Todd Lencz; Anil K. Malhotra; John M. Kane; et al.
Schizophrenia Research. 2009;107(2-3):262-266.15 -
69.
2009Christoph U. Correll; Anne M. Frederickson; Vicki Figen; Elizabeth J. Ginn-Scott; Rudy A. Pantaleon Moya; John M. Kane; Peter Manu
The QTc interval and its dispersion in patients receiving two atypical antipsychotics
European Archives of Psychiatry and Clinical Neuroscience. 2009;259(1):23-27.11 -
70.
2009S. Leucht; J.M. Davis; R.R. Engel; W. Kissling; J.M. Kane
Acta psychiatrica Scandinavica. Supplementum. 2009;(438):7-14.24 -
71.
2009John M. Kane
Journal of Clinical Psychiatry. 2009;70(SUPPL. 3):37-42.8 -
72.
2009John M. Kane; Edward Kim; Hong J. Kan; Zhenchao Guo; John A. Bates; Richard Whitehead; Andrei Pikalov
Applied Health Economics and Health Policy. 2009;7(2):109-119.8 -
73.
2009Prakash S. Masand; Miquel Roca; Martin S. Turner; John M. Kane
Primary Care Companion to the Journal of Clinical Psychiatry. 2009;11(4):147-154.25 -
74.
2009John M. Kane; Carlos Garcia-Ribera
Clinical guideline recommendations for antipsychotic long-acting injections
British Journal of Psychiatry. 2009;195(SUPPL. 52):s63-s67.28 -
75.
2009B.A. Fijal; B.J. Kinon; S. Kapur; V.L. Stauffer; R.R. Conley; H.H. Jamal; J.M. Kane; M.M. Witte; J.P. Houston
Pharmacogenomics Journal. 2009;9(5):311-318.18 -
76.
2009Christoph U. Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M. Kane; Anil K. Malhotra
JAMA - Journal of the American Medical Association. 2009;302(16):1765-1773.240 -
77.
2009Henry A. Nasrallah; Matcheri S. Keshavan; Francine M. Benes; David L. Braff; Alan I. Green; Raquel E. Gur; John M. Kane; Diana O. Perkins; Peter J. Weiden; Daniel R. Weinberger; et al.
Journal of Clinical Psychiatry. 2009;70(SUPPL. 1):4-46.9 -
78.
2008Joan Shen; Kenneth A. Kobak; Yonggang Zhao; Madeline M. Alexander; John M. Kane
Journal of Clinical Psychopharmacology. 2008;28(6):691-693.5 -
79.
2008Pamela DeRosse; Todd Lencz; Katherine E. Burdick; Samuel G. Siris; John M. Kane; Anil K. Malhotra
The genetics of symptom-based phenotypes: Toward a molecular classification of schizophrenia
Schizophrenia Bulletin. 2008;34(6):1047-1053.20 -
80.
2008Mary E. Dankert; Colleen M. Brensinger; Kayla L. Metzger; Chunbo Li; Svetlinka G. Koleva; Andrea Mesén; Béatrice Laprade; Tjhin Wiguna; Changsu Han; Saeed Farooq; et al.
Attitudes of patients and family members towards implantable psychiatric medication
Schizophrenia Research. 2008;105(1-3):279-286.5 -
81.
2008John M. Kane; Sheila Assunção-Talbott; James M. Eudicone; Andrei Pikalov; Richard Whitehead; David T. Crandall
Schizophrenia Research. 2008;105(1-3):208-215.9 -
82.
2008Christoph U. Correll; Christopher W. Smith; Andrea M. Auther; Danielle McLaughlin; Manoj Shah; Carmel Foley; Ruth Olsen; Todd Lencz; John M. Kane; Barbara A. Cornblatt
Journal of Child and Adolescent Psychopharmacology. 2008;18(5):475-490.21 -
83.
2008C. Leucht; M. Kitzmantel; L. Chua; J. Kane; S. Leucht
Haloperidol versus chlorpromazine for treatment of schizophrenia
Schizophrenia Bulletin. 2008;34(5):813-815.0 -
84.
2008Philip R. Szeszko; Colin A. Hodgkinson; Delbert G. Robinson; Pamela DeRosse; Robert M. Bilder; Todd Lencz; Katherine E. Burdick; Barbara Napolitano; Julia D. Betensky; John M. Kane; et al.
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia
Biological Psychology. 2008;79(1):103-110.42 -
85.
2008Sanjiv Kumra; Harvey Kranzler; Ginny Gerbino-Rosen; Hana M. Kester; Courtney DeThomas; Kathyrn Cullen; James Regan; John M. Kane
Journal of Child and Adolescent Psychopharmacology. 2008;18(4):307-316.18 -
86.
2008Julia D. Betensky; Delbert G. Robinson; Handan Gunduz-Bruce; Serge Sevy; Todd Lencz; John M. Kane; Anil K. Malhotra; Rachel Miller; Joanne McCormack; Robert M. Bilder; et al.
Patterns of stress in schizophrenia
Psychiatry Research. 2008;160(1):38-46.14 -
87.
2008John M. Kane
Sedation as a side effect of the treatment of mental disorders
Journal of Clinical Psychiatry. 2008;69(7):e20.2 -
88.
2008Bruce J. Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L. Stauffer; Sara Kollack-Walker; Jennifer L. Sniadecki; John M. Kane
Schizophrenia Research. 2008;102(1-3):230-240.58 -
89.
2008Richard S. E. Keefe; Anil K. Malhotra; Herbert Y. Meltzer; John M. Kane; Robert W. Buchanan; Anita Murthy; Mindy Sovel; Chunming Li; Robert Goldman
Neuropsychopharmacology. 2008;33(6):1217-1228.62 -
90.
2008Baojin Zhu; Haya Ascher-Svanum; Douglas E. Faries; Christoph U. Correll; John M. Kane
Cost of antipsychotic polypharmacy in the treatment of schizophrenia
BMC Psychiatry. 2008;8.24 -
91.
2008Stefan Leucht; Syed Ali Raza Shamsi; Raymonde Busch; Werner Kissling; John M. Kane
Schizophrenia Research. 2008;101(1-3):312-319.22 -
92.
2008John M. Kane; John Lauriello; Eugene Laska; Michael Di Marino; Curt D. Wolfgang
Journal of Clinical Psychopharmacology. 2008;28(7 SUPPL. 1):S29-S35.46 -
93.
2008Christoph U. Correll; John M. Kane; Peter Manu
Journal of Clinical Psychiatry. 2008;69(4):578-583.3 -
94.
2008John M Kane
Relapse prevention in patients with schizophrenia.
The Journal of clinical psychiatry. 2008;69(4):e11.2 -
95.
2008Philip R. Szeszko; Delbert G. Robinson; Manzar Ashtari; Joshua Vogel; Julia Betensky; Serge Sevy; Babak A. Ardekani; Todd Lencz; Anil K. Malhotra; Joanne McCormack; et al.
Neuropsychopharmacology. 2008;33(5):976-984.66 -
96.
2008Sanjiv Kumra; Harvey Kranzler; Ginny Gerbino-Rosen; Hana M. Kester; Courtney DeThomas; Vivian Kafantaris; Christoph U. Correll; John M. Kane
Biological Psychiatry. 2008;63(5):524-529.79 -
97.
2008Stefan Leucht; Stephan Heres; Johannes Hamann; John M. Kane
Methodological issues in current antipsychotic drug trials
Schizophrenia Bulletin. 2008;34(2):275-285.32 -
98.
20081 -
99.
2008John M. Kane; Stefan Leucht
Unanswered questions in schizophrenia clinical trials
Schizophrenia Bulletin. 2008;34(2):302-309.13 -
100.
2008John M. Kane; Roy H. Perlis; Anil K. Malhotra
Clinical insights into pharmacogenetics and schizophrenia, part 1
Journal of Clinical Psychiatry. 2008;69(3):487-494.1 -
101.
2008John M. Kane; Todd Lencz
Cognitive deficits in schizophrenia: Short-term and long-term
World Psychiatry. 2008;7(1):29-30.2 -
102.
2008Brian L. Strom; Gerald A. Faich; Robert F. Reynolds; Sybil M. Eng; Ralph B. D'Agostino; Jeremy N. Ruskin; John M. Kane
Journal of Clinical Psychiatry. 2008;69(1):114-121.19 -
103.
2008John M. Kane; Zafar A. Sharif
Atypical antipsychotics: Sedation versus efficacy
Journal of Clinical Psychiatry. 2008;69(SUPPL. 1):18-31.22 -
104.
2008John M. Kane
An evidence-based strategy for remission in schizophrenia
Journal of Clinical Psychiatry. 2008;69(SUPPL. 3):25-30.10 -
105.
2008Christoph U. Correll; Anne M. Frederickson; John M. Kane; Peter Manu
Bipolar Disorders. 2008;10(7):788-797.60 -
106.
2007Todd Lencz; Christophe Lambert; Pamela DeRosse; Katherine E. Burdick; T. Vance Morgan; John M. Kane; Raju Kucherlapati; Anil K. Malhotra
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia
Proceedings of the National Academy of Sciences of the United States of America. 2007;104(50):19942-19947.87 -
107.
2007Robert A. Lasser; Henry Nasrallah; Lars Helldin; Joseph Peuskens; John Kane; John Docherty; Anselmo Toledo Tronco
Remission in schizophrenia: Applying recent consensus criteria to refine the concept
Schizophrenia Research. 2007;96(1-3):223-231.28 -
108.
2007John M. Kane
Editorial: Schizophrenia International Research Society
Schizophrenia Bulletin. 2007;33(6):1259.0 -
109.
2007Christoph U. Correll; John M. Kane
Journal of Child and Adolescent Psychopharmacology. 2007;17(5):647-655.38 -
110.
2007Irene M. Bratti; John M. Kane; Stephen R. Marder
Chronic restlessness with antipsychotics
American Journal of Psychiatry. 2007;164(11):1648-1654.12 -
111.
2007John M. Kane
Teaching and practicing psychopharmacology
Journal of Clinical Psychiatry. 2007;68(11):1807-1808.0 -
112.
2007Anil K. Malhotra; Todd Lencz; Christoph U. Correll; John M. Kane
Genomics and the future of pharmacotherapy in psychiatry
International Review of Psychiatry. 2007;19(5):523-530.26 -
113.
2007John M. Kane
The management of schizophrenia: Safety, treatment, and continuity of care
CNS Spectrums. 2007;12(10 SUPPL. 17):4.0 -
114.
200731 -
115.
2007Terry E. Goldberg; Robert S. Goldman; Katherine E. Burdick; Anil K. Malhotra; Todd Lencz; Raman C. Patel; Margaret G. Woerner; Nina R. Schooler; John M. Kane; Delbert G. Robinson
Archives of General Psychiatry. 2007;64(10):1115-1122.166 -
116.
2007Dan W Haupt; John M Kane
Metabolic risks and effects of atypical antipsychotic treatment.
The Journal of clinical psychiatry. 2007;68(10):e24.7 -
117.
2007Stefan Leucht; John M. Davis; Rolf R. Engel; John M. Kane; Stefan Wagenpfeil
Neuropsychopharmacology. 2007;32(9):1903-1910.51 -
118.
2007Christoph U. Correll; Julie B. Penzner; Anne M. Frederickson; Jessica J. Richter; Andrea M. Auther; Christopher W. Smith; John M. Kane; Barbara A. Cornblatt
Schizophrenia Bulletin. 2007;33(3):703-714.56 -
119.
2007John M. Kane; David T. Crandall; Ronald N. Marcus; James Eudicone; Andrei Pikalov III; William H. Carson; Wim Swyzen
Schizophrenia Research. 2007;95(1-3):143-150.24 -
120.
2007Handan Gunduz-Bruce; Philip R. Szeszko; Ralitza Gueorguieva; Manzar Ashtari; Delbert G. Robinson; John M. Kane; Robert M. Bilder
Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia
Schizophrenia Research. 2007;94(1-3):281-287.7 -
121.
2007Birgit H. Funke; Todd Lencz; Christine T. Finn; Pamela DeRosse; G. David Poznik; Alex M. Plocik; John Kane; John Rogus; Anil K. Malhotra; Raju Kucherlapati
Analysis of TBX1 variation in patients with psychotic and affective disorders
Molecular Medicine. 2007;13(7-8):407-414.7 -
122.
2007Lars Helldin; John M. Kane; Ulla Karilampi; Torsten Norlander; Trevor Archer
Schizophrenia Research. 2007;93(1-3):160-168.53 -
123.
2007T. Lencz; T.V. Morgan; M. Athanasiou; B. Dain; C.R. Reed; J.M. Kane; R. Kucherlapati; A.K. Malhotra
Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia
Molecular Psychiatry. 2007;12(6):572-580.164 -
124.
2007Christoph U. Correll; Julie B. Penzner; Todd Lencz; Andrea Auther; Christopher W. Smith; Anil K. Malhotra; John M. Kane; Barbara A. Cornblatt
Early identification and high-risk strategies for bipolar disorder
Bipolar Disorders. 2007;9(4):324-338.34 -
125.
2007Handan Gunduz-Bruce; Katherine L. Narr; Ralitza Gueorguieva; Arthur W. Toga; Philip R. Szeszko; Manzar Ashtari; Delbert G. Robinson; Serge Sevy; John M. Kane; Robert M. Bilder
Psychiatry Research - Neuroimaging. 2007;155(1):57-66.2 -
126.
2007Pamela DeRosse; Colin A. Hodgkinson; Todd Lencz; Katherine E. Burdick; John M. Kane; David Goldman; Anil K. Malhotra
Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia
Biological Psychiatry. 2007;61(10):1208-1210.42 -
127.
2007Marc De Hert; Ruud van Winkel; Martien Wampers; John Kane; Jim van Os; Joseph Peuskens
Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort
Schizophrenia Research. 2007;92(1-3):68-73.67 -
128.
2007Christoph U. Correll; Jean L. Harris; Rudy A. Pantaleon Moya; Anne M. Frederickson; John M. Kane; Peter Manu
Schizophrenia Research. 2007;92(1-3):103-107.12 -
129.
2007Barbara A. Cornblatt; Todd Lencz; Christopher W. Smith; Ruth Olsen; Andrea M. Auther; Emilie Nakayama; Martin L. Lesser; Julia Y. Tai; Manoj R. Shah; Carmel A. Foley; et al.
Journal of Clinical Psychiatry. 2007;68(4):546-557.95 -
130.
2007Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Julie C. Locklear; John M. Kane
Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness
Annals of Clinical Psychiatry. 2007;19(2):65-71.11 -
131.
2007Philip R. Szeszko; Delbert G. Robinson; Serge Sevy; Sanjiv Kumra; Claudia I. Rupp; Julia D. Betensky; Todd Lencz; Manzar Ashtari; John M. Kane; Anil K. Malhotra; et al.
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia
British Journal of Psychiatry. 2007;190(MAR.):230-236.30 -
132.
2007John M. Kane; Stefan Leucht; Stephen R. Marder; Delbert G. Robinson; Steven Siegel
New developments in the treatment of schizophrenia
Journal of Clinical Psychiatry. 2007;68(3):463-478.0 -
133.
2007Stefan Leucht; Raymonde Busch; Werner Kissling; John M. Kane
Early prediction of antipsychotic nonresponse among patients with schizophrenia
Journal of Clinical Psychiatry. 2007;68(3):352-360.65 -
134.
2007J. Kane; F. Canas; M. Kramer; L. Ford; C. Gassmann-Mayer; P. Lim; M. Eerdekens
Schizophrenia Research. 2007;90(1-3):147-161.162 -
135.
2007John M. Kane; Herbert Y. Meltzer; William H. Carson Jr.; Robert D. McQuade; Ronald N. Marcus; Raymond Sanchez
Journal of Clinical Psychiatry. 2007;68(2):213-223.71 -
136.
2007Kenneth A. Kobak; John M. Kane; Michael E. Thase; Andrew A. Nierenberg
Journal of Clinical Psychopharmacology. 2007;27(1):1-5.49 -
137.
2007Colin A. Hodgkinson; David Goldman; Francesca Ducci; Pamela DeRosse; Daniel A. Caycedo; Emily R. Newman; John M. Kane; Alec Roy; Anil K. Malhotra
The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations
Neuropsychopharmacology. 2007;32(1):190-196.14 -
138.
2007John M. Kane
Treatment strategies to prevent relapse and encourage remission
Journal of Clinical Psychiatry. 2007;68(SUPPL. 14):27-30.15 -
139.
2007Christoph U. Correll; Anne M. Frederickson; John M. Kane; Peter Manu
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Schizophrenia Research. 2007;89(1-3):91-100.96 -
140.
2006Lars Helldin; John M. Kane; Ulla Karilampi; Torsten Norlander; Trevor Archer
Remission and cognitive ability in a cohort of patients with schizophrenia
Journal of Psychiatric Research. 2006;40(8):738-745.46 -
141.
2006Delbert G. Robinson; Margaret G. Woerner; Barbara Napolitano; Raman C. Patel; Serge M. Sevy; Handan Gunduz-Bruce; Jose M. Soto-Perello; Alan Mendelowitz; Ali Khadivi; Rachel Miller; et al.
American Journal of Psychiatry. 2006;163(12):2096-2102.55 -
142.
2006John M Kane
Utilization of long-acting antipsychotic medication in patient care.
CNS spectrums. 2006;11(12 Suppl 14):1-7; quiz 7-78.13 -
143.
2006Stefan Leucht; John M. Kane
Journal of Clinical Psychiatry. 2006;67(11):1813-1814.27 -
144.
2006Stefan Leucht; John M. Kane; Eva Etschel; Werner Kissling; Johannes Hamann; Rolf R. Engel
Linking the PANSS, BPRS, and CGI: Clinical implications
Neuropsychopharmacology. 2006;31(10):2318-2325.75 -
145.
2006Pamela DeRosse; Birgit Funke; Katherine E. Burdick; Todd Lencz; Terry E. Goldberg; John M. Kane; Raju Kucherlapati; Anil K. Malhotra
COMT genotype and manic symptoms in schizophrenia
Schizophrenia Research. 2006;87(1-3):28-31.10 -
146.
2006Anil K. Malhotra; Katherine E. Burdick; Kamran Razi; John A. Bates; Michael Sanders; John M. Kane
Ziprasidone-induced cognitive enhancement in schizophrenia: Specificity or pseudospecificity?
Schizophrenia Research. 2006;87(1-3):181-184.11 -
147.
200630 -
148.
2006Katherine E. Burdick; Todd Lencz; Birgit Funke; Christine T. Finn; Philip R. Szeszko; John M. Kane; Raju Kucherlapati; Anil K. Malhotra
Genetic variation in DTNBP1 influences general cognitive ability
Human Molecular Genetics. 2006;15(10):1563-1568.108 -
149.
2006John M. Kane
Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Journal of Clinical Psychiatry. 2006;67(5):831-832.20 -
150.
2006Judith Jaeger; Stefanie Berns; Estelle Douglas; Bonnie Creech; Bruce Glick; John Kane
Community-based vocational rehabilitation: Effectiveness and cost impact of a proposed program model
Australian and New Zealand Journal of Psychiatry. 2006;40(5):452-461.3 -
151.
2006Daniel S.G. Umbricht; John A. Bates; Jeffrey A. Lieberman; John M. Kane; Daniel C. Javitt
Biological Psychiatry. 2006;59(8):762-772.73 -
152.
2006Christoph U. Correll; Anne M. Frederickson; John M. Kane; Peter Manu
Journal of Clinical Psychiatry. 2006;67(4):575-583.104 -
153.
2006John Kane
Commentary: Consensus statement on negative symptoms
Schizophrenia Bulletin. 2006;32(2):223-224.5 -
154.
2006Todd Lencz; Delbert G. Robinson; Ke Xu; Jenny Ekholm; Serge Sevy; Handan Gunduz-Bruce; Margaret G. Woerner; John M. Kane; David Goldman; Anil K. Malhotra
American Journal of Psychiatry. 2006;163(3):529-531.74 -
155.
2006Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F. Gattaz; Hans-Jürgen Möller; A. Carlo Altamura; Nancy Andreasen; Thomas R.E. Barnes; Helmut Beckmann; et al.
World Journal of Biological Psychiatry. 2006;7(1):5-40.79 -
156.
2006Pamela DeRosse; Birgit Funke; Katherine E. Burdick; Todd Lencz; Jenny M. Ekholm; John M. Kane; Raju Kucherlapati; Anil K. Malhotra
Dysbindin genotype and negative symptoms in schizophrenia
American Journal of Psychiatry. 2006;163(3):532-534.73 -
157.
2006Robert M. Bilder; Gail Reiter; Jay Bates; Todd Lencz; Philip Szeszko; Robert S. Goldman; Delbert Robinson; Jeffrey A. Lieberman; John M. Kane
Cognitive development in schizophrenia: Follow-back from the first episode
Journal of Clinical and Experimental Neuropsychology. 2006;28(2):270-282.47 -
158.
2006J. Van Os; T. Burns; R. Cavallaro; S. Leucht; J. Peuskens; L. Helldin; M. Bernardo; C. Arango; W. Fleischhacker; B. Lachaux; et al.
Standardized remission criteria in schizophrenia
Acta Psychiatrica Scandinavica. 2006;113(2):91-95.126 -
159.
2006John M. Kane
Review of treatments that can ameliorate nonadherence in patients with schizophrenia
Journal of Clinical Psychiatry. 2006;67(SUPPL. 5):9-14.51 -
160.
2006John M. Kane; Sumant Khanna; Sunita Rajadhyaksha; Earl Giller
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
International Clinical Psychopharmacology. 2006;21(1):21-28.32 -
161.
2006Patrizia A. Cavazzoni; Paul H. Berg; Ludmila A. Kryzhanovskaya; Susan D. Briggs; Tamra E. Roddy; Mauricio Tohen; John M. Kane
Journal of Clinical Psychiatry. 2006;67(1):107-113.24 -
162.
2005Stefan Leucht; John M. Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R. Engel
Schizophrenia Research. 2005;79(2-3):231-238.166 -
163.
2005Joseph P. Rhinewine; Todd Lencz; Emily P. Thaden; Kelly L. Cervellione; Katherine E. Burdick; Inika Henderson; Shree Bhaskar; Lynda Keehlisen; John Kane; Nina Kohn; et al.
Neurocognitive profile in adolescents with early-onset schizophrenia: Clinical correlates
Biological Psychiatry. 2005;58(9):705-712.66 -
164.
2005Frank L. Tornatore; John M. Kane
Journal of Clinical Psychiatry. 2005;66(11):1493-1494.5 -
165.
2005Alan Breier; Paul H. Berg; Jogin H. Thakore; Dieter Naber; Wagner F. Gattaz; Patrizia Cavazzoni; Daniel J. Walker; Suraja M. Roychowdhury; John M. Kane
American Journal of Psychiatry. 2005;162(10):1879-1887.87 -
166.
2005Handan Gunduz-Bruce; Marjorie McMeniman; Delbert G. Robinson; Margaret G. Woerner; John M. Kane; Nina R. Schooler; Jeffrey A. Lieberman
Duration of untreated psychosis and time to treatment response for delusions and hallucinations
American Journal of Psychiatry. 2005;162(10):1966-1969.26 -
167.
2005Stefan Leucht; John M. Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf Engel
Clinical implications of Brief Psychiatric Rating Scale scores
British Journal of Psychiatry. 2005;187(OCT.):366-371.93 -
168.
2005Robert A. Lasser; Cynthia A. Bossie; Georges M. Gharabawi; John M. Kane
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
Schizophrenia Research. 2005;77(2-3):215-227.110 -
169.
2005Sanjiv Kumra; Manzar Ashtari; Kelly L. Cervellione; Inika Henderson; Hana Kester; David Roofeh; Jinghui Wu; Tana Clarke; Emily Thaden; John M. Kane; et al.
Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44(9):934-941.68 -
170.
2005Katherine E. Burdick; Colin A. Hodgkinson; Philip R. Szeszko; Todd Lencz; Jenny M. Ekholm; John M. Kane; David Goldman; Anil K. Malhotra
DISC1 and neurocognitive function in schizophrenia
NeuroReport. 2005;16(12):1399-1402.72 -
171.
2005Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F. Gattaz; Hans-Jürgen Möller; A. Carlo Altamura; Nancy Andreasen; Thomas R.E. Barnes; Helmut Beckmann; et al.
World Journal of Biological Psychiatry. 2005;6(3):132-191.142 -
172.
2005Delbert G. Robinson; Margaret G. Woerner; Howard M. Delman; John M. Kane
Pharmacological treatments for first-episode schizophrenia
Schizophrenia Bulletin. 2005;31(3):705-722.48 -
173.
2005P.R. Szeszko; R. Lipsky; C. Mentschel; D. Robinson; H. Gunduz-Bruce; S. Sevy; M. Ashtari; B. Napolitano; R.M. Bilder; J.M. Kane; et al.
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation
Molecular Psychiatry. 2005;10(7):631-636.177 -
174.
2005Paul Mackin; John M. Kane
Weight gain and antipsychotics [3] (multiple letters)
Journal of Clinical Psychiatry. 2005;66(7):950-951.0 -
175.
2005Stefan Leucht; Raymonde Busch; Johannes Hamann; Werner Kissling; John M. Kane
Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended
Biological Psychiatry. 2005;57(12):1543-1549.113 -
176.
2005David Straker; Christoph U. Correll; Elisse Kramer-Ginsberg; Nasreen Abdulhamid; Fiju Koshy; Elayna Rubens; Robert Saint-Vil; John M. Kane; Peter Manu
American Journal of Psychiatry. 2005;162(6):1217-1221.61 -
177.
2005Douglas E. Faries; Haya Ascher-Svanum; Baojin Zhu; Christoph U. Correll; John Kane
BMC Psychiatry. 2005;5.86 -
178.
2005Susan R. McGurk; Cameron Carter; Robert Goldman; Michael F. Green; Stephen R. Marder; Haiyi Xie; Nina R. Schooler; John M. Kane
The effects of clozapine and risperidone on spatial working memory in schizophrenia
American Journal of Psychiatry. 2005;162(5):1013-1016.27 -
179.
2005John M. Kane
Reading reports of clinical trial results
Journal of Clinical Psychiatry. 2005;66(5):653.2 -
180.
2005Manzar Ashtari; Sanjiv Kumra; Shree L. Bhaskar; Tana Clarke; Emily Thaden; Kelly L. Cervellione; Joseph Rhinewine; John M. Kane; Andrew Adesman; Ruth Milanaik; et al.
Attention-deficit/hyperactivity disorder: A preliminary diffusion tensor imaging study
Biological Psychiatry. 2005;57(5):448-455.122 -
181.
2005Philip R. Szeszko; Babak A. Ardekani; Manzar Ashtari; Sanjiv Kumra; Delbert G. Robinson; Serge Sevy; Handan Gunduz-Bruce; Anil K. Malhotra; John M. Kane; Robert M. Bilder; et al.
American Journal of Psychiatry. 2005;162(3):602-605.110 -
182.
2005Nancy C. Andreasen; William T. Carpenter Jr.; John M. Kane; Robert A. Lasser; Stephen R. Marder; Daniel R. Weinberger
Remission in schizophrenia: Proposed criteria and rationale for consensus
American Journal of Psychiatry. 2005;162(3):441-449.546 -
183.
2005Sudeep Saraf; Prabha S. Chandra; David E. Ross; Christoph U. Correll; John M. Kane; Stefan Leucht
Tardive dyskinesia and second-generation antipsychotics [8] (multiple letters)
American Journal of Psychiatry. 2005;162(2):404-406.1 -
184.
2004John M. Kane; Eugene J. Barrett; Daniel E. Casey; Christoph U. Correll; Alan J. Gelenberg; Samuel Klein; John W. Newcomer
Metabolic effects of treatment with atypical antipsychotics
Journal of Clinical Psychiatry. 2004;65(11):1447-1455.44 -
185.
2004Birgit Funke; Christine T. Finn; Alex M. Plocik; Stephen Lake; Pamela DeRosse; John M. Kane; Raju Kucherlapati; Anil K. Malhotra
Association of the DTNBP1 locus with schizophrenia in a U.S. population
American Journal of Human Genetics. 2004;75(5):891-898.113 -
186.
2004Colin A. Hodgkinson; David Goldman; Judith Jaeger; Shalini Persaud; John M. Kane; Robert H. Lipsky; Anil K. Malhotra
American Journal of Human Genetics. 2004;75(5):862-872.224 -
187.
2004Stephen R. Marder; Susan M. Essock; Alexander L. Miller; Robert W. Buchanan; Daniel E. Casey; John M. Davis; John M. Kane; Jeffrey A. Lieberman; Nina R. Schooler; Nancy Covell; et al.
Physical health monitoring of patients with schizophrenia
American Journal of Psychiatry. 2004;161(8):1334-1349.473 -
188.
2004Vivian Kafantaris; Daniel J. Coletti; Robert Dicker; Gina Padula; Richard R. Pleak; Jose Ma. J. Alvir; John M. Kane
Lithium treatment of acute mania in adolescents: A placebo-controlled discontinuation study
Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43(8):984-993.64 -
189.
2004Sanjiv Kumra; Manzar Ashtari; Marjorie McMeniman; Joshua Vogel; Rachel Augustin; David E. Becker; Emilie Nakayama; Kunsang Gyato; John M. Kane; Kelvin Lim; et al.
Reduced frontal white matter integrity in Early-Onset schizophrenia: A preliminary study
Biological Psychiatry. 2004;55(12):1138-1145.93 -
190.
2004Philip R. Szeszko; John Bates; Delbert Robinson; John Kane; Robert M. Bilder
Schizophrenia Research. 2004;67(2-3):219-225.14 -
191.
2004Manzar Ashtari; Todd Lencz; Paula Zuffante; Robert Bilder; Tana Clarke; Alan Diamond; John Kane; Philip Szeszko
Left middle temporal gyrus activation during a phonemic discrimination task
NeuroReport. 2004;15(3):389-393.11 -
192.
2004Christoph U. Correll; Stefan Leucht; John M. Kane
American Journal of Psychiatry. 2004;161(3):414-425.385 -
193.
2004Alan S. Bellack; Nina R. Schooler; Stephen R. Marder; John M. Kane; Clayton H. Brown; Ye Yang
Do Clozapine and Risperidone Affect Social Competence and Problem Solving
American Journal of Psychiatry. 2004;161(2):364-367.26 -
194.
2004John M. Kane
Guidelines for the use of long-acting injectable atypical antipsychotics
Journal of Clinical Psychiatry. 2004;65(1):120.23 -
195.
2004John M. Kane
Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidence
Journal of Clinical Psychiatry. 2004;65(SUPPL. 9):16-20.69 -
196.
2004Larry Alphs; Ravi Anand; M. Zahur Islam; Herbert Y. Meltzer; John M. Kane; Ranga Krishnan; Alan I. Green; Steven Potkin; Guy Chouinard; Jean-Pierre Lindenmayer; et al.
Schizophrenia Bulletin. 2004;30(3):577-586.19 -
197.
20046 -
198.
2003Philip R Szeszko; Joshua Vogel; Manzar Ashtari; Anil K Malhotra; John Bates; John M Kane; Robert M Bilder; Theresa Frevert; Kelvin Lim
Sex differences in frontal lobe white matter microstructure: a DTI study.
Neuroreport. 2003;14(18):2469-2473.50 -
199.
2003Philip R. Szeszko; Ethan Goldberg; Handan Gunduz-Bruce; Manzar Ashtari; Delbert Robinson; Anil K. Malhotra; Todd Lencz; John Bates; David T. Crandall; John M. Kane; et al.
American Journal of Psychiatry. 2003;160(12):2190-2197.84 -
200.
2003Christoph U. Correll; Anil K. Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M. Kane
Early prediction of antipsychotic response in schizophrenia
American Journal of Psychiatry. 2003;160(11):2063-2065.88 -
201.
2003Samuel J. Keith; John M. Kane
Partial Compliance and Patient Consequences in Schizophrenia: Our Patients Can Do Better
Journal of Clinical Psychiatry. 2003;64(11):1308-1315.116 -
202.
2003Vivian Kafantaris; Daniel J. Coletti; Robert Dicker; Gina Padula; John M. Kane
Lithium treatment of acute mania in adolescents: A large open trial
Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42(9):1038-1045.69 -
203.
2003Margaret G. Woerner; Delbert G. Robinson; Jose Ma. J. Alvir; Brian B. Sheitman; Jeffrey A. Lieberman; John M. Kane
Clozapine as a first treatment for schizophrenia
American Journal of Psychiatry. 2003;160(8):1514-1516.28 -
204.
2003Christopher D. Carlson; Patrizia A. Cavazzoni; Paul H. Berg; Hank Wei; Charles M. Beasley; John M. Kane
Journal of Clinical Psychiatry. 2003;64(8):898-906.34 -
205.
2003Stefan Leucht; Thomas R.E. Barnes; Werner Kissling; Rolf R. Engel; Christoph Correll; John M. Kane
American Journal of Psychiatry. 2003;160(7):1209-1222.318 -
206.
2003John M. Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J. Keith; Michael Lesem; Keith Karcher
American Journal of Psychiatry. 2003;160(6):1125-1132.308 -
207.
2003Patricia Thieda; Stephen Beard; Anke Richter; John Kane
An economic review of compliance with medication therapy in the treatment of schizophrenia
Psychiatric Services. 2003;54(4):508-516.106 -
208.
2003Todd Lencz; Robert M. Bilder; Elihu Turkel; Robert S. Goldman; Delbert Robinson; John M. Kane; Jeffrey A. Lieberman
Archives of General Psychiatry. 2003;60(3):238-243.52 -
209.
2003Herbert Y. Meltzer; Larry Alphs; Alan I. Green; A. Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M. Zahur Islam; John Kane; et al.
Archives of General Psychiatry. 2003;60(1):82-91.499 -
210.
2003John M. Kane
Journal of Clinical Psychiatry. 2003;64(SUPPL. 16):34-40.53 -
211.
2003Stephen R. Marder; Robert Conley; Larry Ereshefsky; John M. Kane; Martin S. Turner
Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone
Journal of Clinical Psychiatry. 2003;64(SUPPL. 16):41-46.22 -
212.
2003John M. Kane; John Krystal; Christoph U. Correll
Treatment Models and Designs for Intervention Research during the Psychotic Prodrome
Schizophrenia Bulletin. 2003;29(4):747-756.15 -
213.
2003John M Kane; Stefan Leucht; Daniel Carpenter; John P Docherty
The Journal of clinical psychiatry. 2003;64 Suppl 12:5-19.212 -
214.
2003John M Kane
Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
The Journal of clinical psychiatry. 2003;64 Suppl 19:3-5.1 -
215.
2003John M Kane
Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
The Journal of clinical psychiatry. 2003;64 Suppl 19:19-25.19 -
216.
2002John M. Kane; William H. Carson; Anutosh R. Saha; Robert D. McQuade; Gary G. Ingenito; Dan L. Zimbroff; Mirza W. Ali
Journal of Clinical Psychiatry. 2002;63(9):763-771.421 -
217.
2002Siow-Ann Chong; Mythily; Alvin Lum; Chan Yiong Huak; John Kane
Tardive dyskinesia and impaired glucose tolerance
Human Psychopharmacology. 2002;17(6):305-307.4 -
218.
2002Handan Gunduz; Huwei Wu; Manzar Ashtari; Bernhard Bogerts; David Crandall; Delbert G Robinson; Jose Alvir; Jeffrey Lieberman; John Kane; Robert Bilder
Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects
Biological Psychiatry. 2002;51(10):801-808.52 -
219.
2002Stephen R. Marder; Susan M. Essock; Alexander L. Miller; Robert W. Buchanan; John M. Davis; John M. Kane; Jeffrey Lieberman; Nina R. Schooler
The Mount Sinai Conference on the pharmacotherapy of schizophrenia
Schizophrenia Bulletin. 2002;28(1):5-16.82 -
220.
2002Siow-Ann Chong; Rathi Mahendran; David Machin; Hong-Choon Chua; Gordon Parker; John Kane
Tardive dyskinesia among Chinese and Malay patients with schizophrenia
Journal of Clinical Psychopharmacology. 2002;22(1):26-30.15 -
221.
2002John M. Kane; John M. Davis; Nina Schooler; Stephen Marder; Daniel Casey; Benjamin Brauzer; Jim Mintz; Robert Conley
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia
American Journal of Psychiatry. 2002;159(4):554-560.35 -
222.
2002Daniel S. Umbricht; William C. Wirshing; Donna A. Wirshing; Marjorie McMeniman; Nina R. Schooler; Stephen R. Marder; John M. Kane
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia
Journal of Clinical Psychiatry. 2002;63(5):420-424.34 -
223.
2002Roy H. Perlis; Gary S. Sachs; Beny Lafer; Michael W. Otto; Stephen V. Faraone; John M. Kane; Jerrold F. Rosenbaum
American Journal of Psychiatry. 2002;159(7):1155-1159.47 -
224.
2002Gwenn S. Smith; Yilong Ma; Vijay Dhawan; Handan Gunduz; Maren Carbon; Maggie Kirshner; Jennifer Larson; Thomas Chaly; Abdel Belakhleff; Elisse Kramer; et al.
Synapse. 2002;45(2):105-112.35 -
225.
2002John M Kane
Extending indications for long-term pharmacotherapy: opportunities and challenges.
American Journal of Psychiatry. 2002;159(1):1-2.4 -
226.
2001Barbara A. Cornblatt; Todd Lencz; John M. Kane
Treatment of the schizophrenia prodrome: Is it presently ethical?
Schizophrenia Research. 2001;51(1):31-38.88 -
227.
2001J. Kane
Progress defined - Short-term efficacy, long-term effectiveness
International Clinical Psychopharmacology. 2001;16(SUPPL. 1):S1-S8.29 -
228.
2001Vivian Kafantaris; Robert Dicker; Daniel J. Coletti; John M. Kane
Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania
Journal of Child and Adolescent Psychopharmacology. 2001;11(4):409-413.25 -
229.
2001Serge Sevy; Delbert G. Robinson; Scott Holloway; Jose M. Alvir; Margaret G. Woerner; Robert Bilder; Robert Goldman; Jeffrey Lieberman; John Kane
Acta Psychiatrica Scandinavica. 2001;104(5):367-374.99 -
230.
2001Vivian Kafantaris; Daniel J. Coletti; Robert Dicker; Gina Padula; John M. Kane
Adjunctive antipsychotic treatment of adolescents with bipolar psychosis
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(12):1448-1456.63 -
231.
2001John M. Kane; Stephen R. Marder; Nina R. Schooler; William C. Wirshing; Daniel Umbricht; Robert W. Baker; Donna A. Wirshing; Allan Safferman; Rohan Ganguli; Marjorie McMeniman; et al.
Archives of General Psychiatry. 2001;58(10):965-972.113 -
232.
2001John Kane
Extrapyramidal side effects are unacceptable
European Neuropsychopharmacology. 2001;11(SUPPL. 4):S397-S403.83 -
233.
2001R.H. Chaplin; D.V. Jeste; A. Okamoto; J. Napolitano; J.M. Kane; R.A. Martinez
Risperidone, tardive dyskinesia, and the elderly [10]
American Journal of Psychiatry. 2001;158(8):1336-1337.1 -
234.
2001John M. Kane
Dose selection and comparator drugs in schizophrenia research
Journal of Clinical Psychiatry. 2001;62(SUPPL. 9):29-34.7 -
235.
2000Dilip V. Jeste; Akiko Okamoto; Judy Napolitano; John M. Kane; Rick A. Martinez
American Journal of Psychiatry. 2000;157(7):1150-1155.124 -
236.
2000Robert M. Bilder; Robert S. Goldman; Delbert Robinson; Gail Reiter; Lisa Bell; John A. Bates; Elizabeth Pappadopulos; Deborah F. Willson; Jose Maria J. Alvir; Margaret G. Woerner; et al.
Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates
American Journal of Psychiatry. 2000;157(4):549-559.502 -
237.
2000Bruce L. Saltz; Margaret G. Woerner; Delbert G. Robinson; John M. Kane
Side effects of antipsychotic drugs: Avoiding and minimizing their impact in elderly patients
Postgraduate Medicine. 2000;107(2):169-178.7 -
238.
199993 -
239.
1999Gary D. Tollefson; Mary Anne Dellva; Carole A. Mattler; John M. Kane; Donna A. Wirshing; Bruce J. Kinon; Donna Ames; Cal K. Cohn; David G. Daniel; Scott C. Clark; et al.
Journal of Clinical Psychopharmacology. 1999;19(5):435-443.30 -
240.
1999Marcella Rietschel; Jim L. Kennedy; Fabio Macciardi; Herbert Y. Meltzer; A. Breier; L.E. DeLisi; F Henn; W. Kalow; R. Kerwin; J. Kurth; et al.
Schizophrenia Research. 1999;37(2):191-196.29 -
241.
1999J. Kane
Olanzapine in the long-term treatment of schizophrenia.
The British journal of psychiatry. Supplement. 1999;(37):26-29.15 -
242.
1999John M. Kane
Tardive dyskinesia in affective disorders
Journal of Clinical Psychiatry. 1999;60(SUPPL. 5):43-49.59 -
243.
1999John M. Kane
Management strategies for the treatment of schizophrenia
Journal of Clinical Psychiatry. 1999;60(SUPPL. 12):13-17.51 -
244.
1998Margaret G. Woerner; Jose Ma. J. Alvir; Bruce L. Saltz; Jeffrey A. Lieberman; John M. Kane
Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
American Journal of Psychiatry. 1998;155(11):1521-1528.135 -
245.
1998Daniel Umbricht; Daniel Javitt; Gerald Novak; John Bates; Simcha Pollack; Jeffrey Lieberman; John Kane
Effects of clozapine on auditory event-related potentials in schizophrenia
Biological Psychiatry. 1998;44(8):716-725.132 -
246.
1998John M. Kane
Sertindole: A review of clinical efficacy
International Clinical Psychopharmacology. 1998;13(SUPPL. 3):S59-S64.16 -
247.
1998John M. Kane; Eugenio Aguglia; A. Carlo Altamura; José Luis Ayuso Gutierrez; Nicoletta Brunello; W. Wolfgang Fleischhacker; Wolfang Gaebel; Jes Gerlach; Julien-D. Guelfi; Werner Kissling; et al.
Guidelines for depot antipsychotic treatment in schizophrenia
European Neuropsychopharmacology. 1998;8(1):55-66.201 -
248.
1998R.J. Baldessarini; A.C. Viguera; W.T. Carpenter; N.R. Schooler; J.M. Kane
Medication removal and research in psychotic disorders [5] (multiple letters)
Archives of General Psychiatry. 1998;55(3):281-282.3 -
249.
1998Simcha Pollack; Margaret G. Woerner; Alfreda Howard; Robert B. Fireworker; John M. Kane
Clozapine reduces rehospitalization among schizophrenia patients
Psychopharmacology Bulletin. 1998;34(1):89-92.21 -
250.
1998G. Remington; S. Kapur; R. Zipursky; S.R. Marder; R. Liberman; P. Wang; D.A. Zarin; R. Balon; J.A. Mattes; D.L. Zimbroff; et al.
APA practice guideline for schizophrenia: Risperidone equivalents [6]
American Journal of Psychiatry. 1998;155(9):1301-1304.6 -
251.
1997Dan L. Zimbroff; John M. Kane; Carol A. Tamminga; David G. Daniel; Randall J. Mack; Patricia J. Wozniak; Terri B. Sebree; Bruce A. Wallin; Kenneth B. Kashkin
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
American Journal of Psychiatry. 1997;154(6):782-791.274 -
252.
1997Nina R. Schooler; Samuel J. Keith; Joanne B. Severe; Susan M. Matthews; Alan S. Bellack; Ira D. Glick; William A. Hargreaves; John M. Kane; Philip T. Ninan; Allen Frances; et al.
Archives of General Psychiatry. 1997;54(5):453-463.196 -
253.
1997William T. Carpenter Jr.; Nina R. Schooler; John M. Kane
The rationale and ethics of medication-free research in schizophrenia
Archives of General Psychiatry. 1997;54(5):401-407.84 -
254.
1997John M. Kane
The use of scales for clinical monitoring of disease progression and the treatment of schizophrenia
Neuropsychobiology. 1997;35(2):64-66.1 -
255.
1997John M. Kane
What can we achieve by implementing a compliance-improvement program?
International Clinical Psychopharmacology. 1997;12(SUPPL. 1):S43-S46.7 -
256.
1997Wayne S. Fenton; John M. Kane
Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction
Schizophrenia Bulletin. 1997;23(4):563-565.2 -
257.
1997C.A. Tamminga; J.M. Kane
Olanzapine (Zyprexa): Characteristics of a new antipsychotic
Expert Opinion on Investigational Drugs. 1997;6(11):1743-1752.7 -
258.
1997J.M. Kane; C.A. Tamminga
Sertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic
Expert Opinion on Investigational Drugs. 1997;6(11):1729-1741.23 -
259.
1997John M. Kane
What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?
International Clinical Psychopharmacology. 1997;12(SUPPL. 2):S3-S6.8 -
260.
1996J.M. Kane
Factors which can make patients difficult to treat.
The British journal of psychiatry. Supplement. 1996;(31):10-14.18 -
261.
1996J.M. Kane
Commentary on the clozapine conflict.
The American journal of psychiatry. 1996;153(11):1507-1508.7 -
262.
1996David A. Solomon; W. Richard Ristow; Martin B. Keller; John M. Kane; Alan J. Gelenberg; Jerrold F. Rosenbaum; Meredith G. Warshaw
Serum lithium levels and psychosocial function in patients with bipolar I disorder
American Journal of Psychiatry. 1996;153(10):1301-1307.38 -
263.
1996Miranda H. Chakos; Jose Ma. J. Alvir; Margaret G. Woerner; Amy Koreen; Stephen Geisler; David Mayerhoff; Steven Sobel; John M. Kane; Michael Borenstein; Jeffrey A. Lieberman
Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
Archives of General Psychiatry. 1996;53(4):313-319.95 -
264.
1996Sally Szymanski; Jeffrey Lieberman; Simcha Pollack; John M. Kane; Allan Safferman; Raphael Munne; Daniel Umbricht; Margaret Woerner; Stephen Masiar; Michael Kronig
Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics
Biological Psychiatry. 1996;39(4):249-254.49 -
265.
1996277 -
266.
1996J.M. Kane; C.A. Tamminga; N.R. Schooler; D.E. Casey
Choosing among old and new antipsychotics
Journal of Clinical Psychiatry. 1996;57(9):427-438.7 -
267.
1996D. Ames; W.C. Wirshing; R.W. Baker; D.S.G. Umbricht; A.B. Sun; J. Carter; N.R. Schooler; J.M. Kane; S.R. Marder
Predictive value of eosinophilia for neutropenia during clozapine treatment
Journal of Clinical Psychiatry. 1996;57(12):579-581.13 -
268.
19963 -
269.
1996M.G. Woerner; B.B. Sheitman; J.A. Lieberman; J.M. Kane
Tardive dyskinesia induced by risperidone? [9]
American Journal of Psychiatry. 1996;153(6):843.47 -
270.
1996Jr. Carpenter W.T.; R.R. Conley; R.W. Buchanan; A. Breier; C.A. Tamminga; J.M. Kane
American Journal of Psychiatry. 1996;153(11):1505-1508.4 -
271.
1996Daniel Umbricht; John M. Kane
Medical complications of new antipsychotic drugs
Schizophrenia Bulletin. 1996;22(3):475-483.65 -
272.
1996John M. Kane
Treatment-resistant schizophrenic patients
Journal of Clinical Psychiatry. 1996;57(SUPPL. 9):35-40.60 -
273.
1996J.M. Kane
Impact of recent economic changes in psychiatry on academic psychiatry programs
American Journal of Psychiatry. 1996;153(3):307-308.0 -
274.
199554 -
275.
1995M.G. Woerner; J.M.J. Alvir; J.M. Kane; B.L. Saltz; J.A. Lieberman
Neuroleptic treatment of elderly patients
Psychopharmacology Bulletin. 1995;31(2):333-337.14 -
276.
1995A. Chatterjee; M. Chakos; A. Koreen; S. Geisler; B. Sheitman; M. Woerner; J.M. Kane; J. Alvir; J.A. Lieberman
American Journal of Psychiatry. 1995;152(12):1724-1729.146 -
277.
1995M.H. Kronig; R.A. Munne; S. Szymanski; A.Z. Safferman; S. Pollack; T. Cooper; J.M. Kane; J.A. Lieberman
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
American Journal of Psychiatry. 1995;152(2):179-182.144 -
278.
1995Sally Szymanski; Jeffrey Lieberman; Simcha Pollack; Allan Safferman; Rafael Munne; Daniel Umbricht; John Kane; Michael Kronig; Miranda Chakos; Thomas Cooper
Biological Psychiatry. 1995;37(1):52-55.12 -
279.
1995S. Szymanski; J.A. Lieberman; J.M. Alvir; D. Mayerhoff; A. Loebel; S. Geisler; M. Chakos; A. Koreen; D. Jody; J. Kane; et al.
American Journal of Psychiatry. 1995;152(5):698-703.188 -
280.
199574 -
281.
1995J.M. Kane
Antipsychotic medication in the treatment of schizophrenia.
Israel Journal of Psychiatry and Related Sciences. 1995;32(1):30-37.2 -
282.
1995J.M. Kane
Dosing issues and depot medication in the maintenance treatment of schizophrenia
International Clinical Psychopharmacology. 1995;10(SUPPL. 3):65-71.17 -
283.
1994Jeffrey A. Lieberman; Allan Z. Safferman; Simcha Pollack; Sally Szymanski; Celeste Johns; Alfreda Howard; Michael Kronig; Peter Bookstein; John M. Kane
American Journal of Psychiatry. 1994;151(12):1744-1752.252 -
284.
1994J.M. Kane; H.L. Freeman
Towards more effective antipsychotic treatment.
The British journal of psychiatry. Supplement. 1994;(25):22-31.10 -
285.
1994J.M. Kane
British Journal of Psychiatry. 1994;164(4):431-432.15 -
286.
1994S. Szymanski; S. Masiar; D. Mayerhoff; A. Loebel; S. Geisler; S. Pollack; J. Kane; J. Lieberman
Clozapine response in treatment-refractory first-episode schizophrenia
Biological Psychiatry. 1994;35(4):278-280.25 -
287.
1994A.M. Fuchs; J.M. Kane; S.R. Marder
Clozapine: Benefits and risks [1]
Schizophrenia Bulletin. 1994;20(1):23-24.2 -
288.
199419 -
289.
1994Amy R. Koreen; Jeffrey Lieberman; Jose Alvir; Miranda Chakos; Antony Loebel; Thomas Cooper; John Kane
American Journal of Psychiatry. 1994;151(1):35-39.3 -
290.
1994W.W. Fleischhacker; M. Hummer; M. Kurz; I. Kurzthaler; J.A. Lieberman; S. Pollack; A.Z. Safferman; J.M. Kane
Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):78-81.50 -
291.
1994J.M. Kane; A.Z. Safferman; S. Pollack; C. Johns; S. Szymanski; M. Kronig; J.A. Lieberman
Clozapine, negative symptoms, and extrapyramidal side effects
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):74-77.26 -
292.
1994R.M. Bilder; H. Wu; M.H. Chakos; B. Bogerts; S. Pollack; J. Aronowitz; M. Ashtari; G. Degreef; J.M. Kane; J.A. Lieberman
Cerebral morphometry and clozapine treatment in schizophrenia
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):53-56.43 -
293.
1994D.S.G. Umbricht; S. Pollack; J.M. Kane
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):157-160.168 -
294.
1994R. Balon; W.M. Glazer; J.M. Kane
The underutilization of depot neuroleptic therapy [6]
Journal of Clinical Psychiatry. 1994;55(1):39.3 -
295.
1994J.A. Lieberman; J. Alvir; S. Geisler; J. Ramos-Lorenzi; M. Woerner; H. Novacenko; T. Cooper; J.M. Kane
Neuropsychopharmacology. 1994;11(2):107-118.39 -
296.
1994J.M. Kane
Introduction. Risperidone: New horizons for the schizophrenic patient
Journal of Clinical Psychiatry. 1994;55(5 SUPPL.):3-4.4 -
297.
1994J.A. Lieberman; J.M. Kane; A.Z. Safferman; S. Pollack; A. Howard; S. Szymanski; S.J. Masiar; M.H. Kronig; T. Cooper; H. Novacenko
Predictors of response to clozapine
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):126-128.48 -
298.
1994A.Z. Safferman; J.M. Kane; J.S. Aronowitz; M.F. Gordon; S. Pollack; J.A. Lieberman
The use of clozapine in neurologic disorders
Journal of Clinical Psychiatry. 1994;55(9 SUPPL. B):98-101.32 -
299.
1993John M. Kane
Newer antipsychotic drugs: A review of their pharmacology and therapeutic potential
Drugs. 1993;46(4):585-593.28 -
300.
1993S. Szymanski; J. Lieberman; S. Pollack; R. Munne; A. Safferman; J. Kane; M. Kronig; T. Cooper
The dopamine-serotonin relationship in clozapine response
Psychopharmacology. 1993;112(1 Supplement):S85-S89.24 -
301.
1993A.Z. Safferman; J.A. Lieberman; S. Pollack; J.M. Kane
Akathisia and clozapine treatment [1]
Journal of Clinical Psychopharmacology. 1993;13(4):286-287.18 -
302.
1993J.M. Davis; J.M. Kane; S.R. Marder; B. Brauzer; B. Gierl; N. Schooler; D.E. Casey; M. Hassan
Dose response of prophylactic antipsychotics
Journal of Clinical Psychiatry. 1993;54(3 SUPPL.):24-30.74 -
303.
1993J.M. Kane
Residual and negative symptoms in treatment with neuroleptics.
Psychopharmacology series. 1993;10:131-137.1 -
304.
1993S. Pollack; J. Lieberman; D. Kleiner; S. Szymanski; J. Kane; M. Borenstein; T. Cooper
High plasma clozapine levels in tardive dyskinesia
Psychopharmacology Bulletin. 1993;29(2):257-262.8 -
305.
1993W.W. Fleischhacker; C.H. Miller; C. Barnas; K. Bergmann; R. Perovich; J.M. Alvir; J.A. Lieberman; J.M. Kane
The effect of activation procedures on neuroleptic-induced akathisia
British Journal of Psychiatry. 1993;163(DEC.):781-784.10 -
306.
1993R. Tandon; J.M. Kane
Neuropharmacologic basis for clozapine's unique profile [2]
Archives of General Psychiatry. 1993;50(2):158-159.14 -
307.
1993B.J. Kinon; J.M. Kane; C. Johns; R. Perovich; M. Ismi; A. Koreen; P. Weiden
Treatment of neuroleptic-resistant schizophrenic relapse
Psychopharmacology Bulletin. 1993;29(2):309-314.92 -
308.
1993J.M. Kane; M.G. Woerner; S. Pollack; A.Z. Safferman; J.A. Lieberman
Does clozapine cause tardive dyskinesia?
Journal of Clinical Psychiatry. 1993;54(9):327-330.114 -
309.
1993B.J. Kinon; J.M. Kane; M. Chakos; R. Munne
Psychopharmacology Bulletin. 1993;29(3):365-369.23 -
310.
1993Margaret G. Woerner; Bruce L. Saltz; John M. Kane; Jeffrey A. Lieberman; Jose M. J. Alvir
Diabetes and development of tardive dyskinesia
American Journal of Psychiatry. 1993;150(6):966-968.45 -
311.
1993J.M. Kane; S.R. Marder
Psychopharmacologic treatment of schizophrenia
Schizophrenia Bulletin. 1993;19(2):287-302.172 -
312.
1993J.M. Kane; D. Dauphinals; T.R.E. Barnes; L.A. Adler; A. Rifkin
Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: Workshop report
Psychopharmacology Bulletin. 1993;29(1):45-49.5 -
313.
1993G.N. Peterson; J.M. Kane
Psychopharmacological Screening Criteria [4]
Journal of Clinical Psychiatry. 1993;54(10):397-398.0 -
314.
1993Daniel S.G. Umbricht; Bruce Saltz; Simcha Pollack; Margaret Woerner; John M. Kane; Jeffrey A. Lieberman
Polydipsia and tardive dyskinesia in chronic psychiatric patients - Related disorders?
American Journal of Psychiatry. 1993;150(10):1536-1538.9 -
315.
1992J.M. Kane; D.L. Evans; S.J. Fiester; S.M. Mirin; H.A. Pincus; A.F. Schatzberg; J.O. Cole; C.W. Popper
Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments.
Journal of Clinical Psychiatry. 1992;53(6):184-196.12 -
316.
1992J.M. Kane
Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview.
The British journal of psychiatry. Supplement. 1992;(17):41-45.40 -
317.
1992Allan Zachary Safferman; Jeffrey Alan Lieberman; Simcha Pollack; John M. Kane
Biological Psychiatry. 1992;31(7):753-754.4 -
318.
1992Janet B.W. Williams; Miriam Gibbon; Michael B. First; Robert L. Spitzer; Mark Davies; Jonathan Borus; Mary J. Howes; John Kane; Harrison C. Pope Jr.; Bruce Rounsaville; et al.
The structured clinical interview for DSM-III-R (SCID) II. Multisite test-retest reliability
Archives of General Psychiatry. 1992;49(8):630-636.856 -
319.
1992J.A. Lieberman; J.M.J. Alvir; M. Woerner; G. Degreef; R.M. Bilder; M. Ashtari; B. Bogerts; D.I. Mayerhoff; S.H. Geisler; A. Loebel; et al.
Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital
Schizophrenia Bulletin. 1992;18(3):351-371.111 -
320.
1992J.M. Kane
Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics
Psychopharmacology Bulletin. 1992;28(3):227-229.2 -
321.
1992J.M. Kane
New developments in the pharmacological treatment of schizophrenia
Bulletin of the Menninger Clinic. 1992;56(1):62-75.5 -
322.
1992Martin B. Keller; Philip W. Lavori; John M. Kane; Alan J. Gelenberg; Jerrold F. Rosenbaum; Elizabeth A. Walzer; Lori A. Baker
Subsyndromal symptoms in bipolar disorder: A comparison of standard and low serum levels of lithium
Archives of General Psychiatry. 1992;49(5):371-376.141 -
323.
1991J.A. Lieberman; B.L. Saltz; C.A. Johns; S. Pollack; M. Borenstein; J. Kane
The effects of clozapine on tardive dyskinesia
British Journal of Psychiatry. 1991;158(APR.):503-510.200 -
324.
19917 -
325.
1991J.M. Kane
New developments in the pharmacologic treatment of schizophrenia: Editor's introduction
Schizophrenia Bulletin. 1991;17(2):193-195.0 -
326.
1991M.G. Woerner; J.M. Kane; J.A. Lieberman; J. Alvir; K.J. Bergmann; M. Borenstein; N.R. Schooler; S. Mukherjee; J. Rotrosen; M. Rubinstein; et al.
The prevalence of tardive dyskinesia
Journal of Clinical Psychopharmacology. 1991;11(1):34-42.86 -
327.
1991B.L. Saltz; M.G. Woerner; J.M. Kane; J.A. Lieberman; J.M.J. Alvir; K.J. Bergmann; K. Blank; J. Koblenzer; K. Kahaner
Prospective study of tardive dyskinesia incidence in the elderly
Journal of the American Medical Association. 1991;266(17):2402-2406.140 -
328.
1991A. Safferman; J.A. Lieberman; J.M. Kane; S. Szymanski; B. Kinon
Update on the clinical efficacy and side effects of clozapine
Schizophrenia Bulletin. 1991;17(2):247-261.136 -
329.
1991J.M. Kane
Obstacles to clinical research and new drug development in schizophrenia
Schizophrenia Bulletin. 1991;17(2):353-356.2 -
330.
1991J.M. Kane; J. Selzer
Considerations on 'organic' exclusion criteria for schizophrenia
Schizophrenia Bulletin. 1991;17(1):69-73.2 -
331.
1991S. Szymanski; J.M. Kane; J.A. Lieberman
A selective review of biological markers in schizophrenia
Schizophrenia Bulletin. 1991;17(1):99-111.30 -
332.
1990J.M. Kane
Treatment programme and long-term outcome in chronic schizophrenia.
Acta Psychiatrica Scandinavica, Supplement. 1990;358:151-157.13 -
333.
1990C.H. Miller; W.W. Fleischhacker; H. Ehrmann; J.M. Kane
Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin
Psychopharmacology Bulletin. 1990;26(3):373-376.55 -
334.
19901 -
335.
1990Jeffrey A. Lieberman; Juan Yunis; Eduardo Egea; Rosa T. Canoso; John M. Kane; Edmond J. Yunis
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with Schizophrenia
Archives of General Psychiatry. 1990;47(10):945-948.96 -
336.
1990W.W. Fleischhacker; B. Unterweger; J.M. Kane; H. Hinterhuber
The neuroleptic malignant syndrome and its differentiation from lethal catatonia
Acta Psychiatrica Scandinavica. 1990;81(1):3-5.19 -
337.
1989J.M. Kane; D. Mayerhoff
Do negative symptoms respond to pharmacological treatment?
The British journal of psychiatry. Supplement. 1989;(7):115-118.15 -
338.
1989Bruce J. Kinon; John M. Kane
Psychopharmacology. 1989;98(4):465-471.8 -
339.
1989Jeffrey Lieberman; Celeste Johns; Thomas Cooper; Simcha Pollack; John Kane
Clozapine pharmacology and tardive dyskinesia
Psychopharmacology. 1989;99(1 Supplement):S54-S59.36 -
340.
1989J.A. Lieberman; J.M. Kane; C.A. Johns
Clozapine: Guidelines for clinical management
Journal of Clinical Psychiatry. 1989;50(9):329-338.132 -
341.
1989J.A. Lieberman; J. Alvir; S. Mukherjee; J.M. Kane
Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy
Archives of General Psychiatry. 1989;46(10):908-913.15 -
342.
1989W.W. Fleischhacker; K.J. Bergmann; R. Perovich; L.K. Pestreich; M. Borenstein; J.A. Lieberman; J.M. Kane
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia
Psychopharmacology Bulletin. 1989;25(2):222-226.53 -
343.
1989J.M. Kane
The current status of neuroleptic therapy
Journal of Clinical Psychiatry. 1989;50(9):322-328.74 -
344.
1989W.A. Hargreaves; J.M. Kane; P.T. Ninan; J.B. Severe; M. Woerner
Psychopharmacology Bulletin. 1989;25(3):340-343.3 -
345.
1989J.A. Lieberman; B.L. Saltz; C.A. Johns; S. Pollack; J.M. Kane
Clozapine effects on tardive dyskinesia
Psychopharmacology Bulletin. 1989;25(1):57-62.21 -
346.
1989B.L. Saltz; J.M. Kane; M.G. Woerner; J.A. Lieberman; J.M.J. Alvir; K. Blank; K. Kahaner; C. Foley
Prospective study of tardive dyskinesia in the elderly
Psychopharmacology Bulletin. 1989;25(1):52-56.19 -
347.
1988J.M. Kane; M. Woerner; J. Lieberman
Epidemiological aspects of tardive dyskinesia
Encephale. 1988;14(SPEC. ISS.):191-194.10 -
348.
1988S.G. Siris; J.M. Kane; K. Frechen; A.P. Sellew; J. Mandeli
Patterns of previous drug abuse in patients presenting with postpsychotic depression
Psychopharmacology Bulletin. 1988;24(2):256-259.1 -
349.
1988J. Lieberman; M. Lesser; C. Johns; S. Pollack; B. Saltz; J. Kane
Pharmacologic studies of tardive dyskinesia
Journal of Clinical Psychopharmacology. 1988;8(4 SUPPL.):57S-63S.18 -
350.
1988J.M. Kane; M. Woerner; J. Lieberman
Tardive dyskinesia: Prevalence, incidence, and risk factors
Journal of Clinical Psychopharmacology. 1988;8(4 SUPPL.):52S-56S.165 -
351.
1988D. Kreisman; R. Blumenthal; M. Borenstein; M. Woerner; J. Kane; A. Rifkin; G. Reardon
Psychiatry. 1988;51(1):3-13.26 -
352.
1988J.A. Lieberman; C.A. Johns; J.M. Kane; K. Rai; A.V. Pisciotta; B.L. Saltz; A. Howard
Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs
Journal of Clinical Psychiatry. 1988;49(7):271-277.82 -
353.
1988J. Lieberman; S. Pollack; M. Lesser; J. Kane
Pharmacologic characterization of tardive dyskinesia
Journal of Clinical Psychopharmacology. 1988;8(4):254-260.14 -
354.
1988J. Kane; G. Honigfeld; J. Singer; H. Meltzer
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
Archives of General Psychiatry. 1988;45(9):789-796.2191 -
355.
1988M.G. Woerner; S. Mannuzza; J.M. Kane
Anchoring the BPRS: An aid to improved reliability
Psychopharmacology Bulletin. 1988;24(1):112-117.231 -
356.
1988J.M. Kane; G. Honigfeld; J. Singer; H. Meltzer
Clozapine in treatment-resistant schizophrenics
Psychopharmacology Bulletin. 1988;24(1):62-67.105 -
357.
1988H. Goldman; M.J. Goldstein; G.E. Hogarty; D. Jeste; J.M. Kane; G.L. Klerman; R.P. Liberman; S.M. Paul; D.S. Robinson; B. Spring; et al.
Treatment, services, and environmental factors
Schizophrenia Bulletin. 1988;14(3):427-437.4 -
358.
1988S.G. Siris; J.M. Kane; K. Frechen; A.P. Sellew; J. Mandeli; B. Fasano-Dube
Histories of substance abuse in patients with postpsychotic depressions
Comprehensive Psychiatry. 1988;29(6):550-557.15 -
359.
1988J.M. Kane
The role of neuroleptics in manic-depressive illness
Journal of Clinical Psychiatry. 1988;49(11 SUPPL. NOV.):12-13.46 -
360.
1988J.M.J. Alvir; N.R. Schooler; M.T. Borenstein; M.G. Woerner; J.M. Kane
The reliability of a shortened version of the SCL-90
Psychopharmacology Bulletin. 1988;24(2):242-246.10 -
361.
1987J.A. Lieberman; J.M. Kane; J. Alvir
Provocative tests with psychostimulant drugs in schizophrenia
Psychopharmacology. 1987;91(4):415-433.215 -
362.
1987J.A. Lieberman; J.M. Kane; S. Sarantakos; D. Gadaleta; M. Woerner; J. Alvir; J. Ramos-Lorenzi
Prediction of relapse in schizophrenia
Archives of General Psychiatry. 1987;44(7):597-603.31 -
363.
198768 -
364.
1986C.J. Rabiner; J.T. Wegner; J.M. Kane
Outcome study of first-episode psychosis, I: Relapse rates after 1 year
American Journal of Psychiatry. 1986;143(9):1155-1158.71 -
365.
1986J.M. Kane
Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate
Journal of Clinical Psychopharmacology. 1986;6(1 SUPPL.):20S-23S.5 -
366.
1986J.M. Kane; M. Woerner; M. Borenstein; J. Wegner; J. Lieberman
Integrating incidence and prevalence of tardive dyskinesia
Psychopharmacology Bulletin. 1986;22(1):254-258.110 -
367.
1986J.A. Lieberman; J.M. Kane; S. Sarantakos; D. Gadaletta; M. Woerner; J. Alvir; J. Ramos-Lorenzi
Prediction of relapse in schizophrenia
Psychopharmacology Bulletin. 1986;22(3):845-853.0 -
368.
1985James T. Wegner; John M. Kane; Paul Weinhold; Margaret Woerner; Bruce Kinon; Jeffrey Lieberman
Cognitive impairment in tardive dyskinesia
Psychiatry Research. 1985;16(4):331-337.16 -
369.
1985Jeffrey A. Lieberman; Thomas B. Cooper; Raymond F. Suckow; Herbert Steinberg; Michael Borenstein; Ronald Brenner; John M. Kane
Tricyclic antidepressant and metabolite levels in chronic renal failure
Clinical Pharmacology and Therapeutics. 1985;37(3):301-307.26 -
370.
1985J.M. Kane; A. Rifkin; M. Woerner; G. Reardon; D. Kreisman; R. Blumenthal; M. Borenstein
High-dose versus low-dose strategies in the treatment of schizophrenia
Psychopharmacology Bulletin. 1985;21(3):533-537.16 -
371.
1985R. Gruen; M. Baron; M. Levitt; J. Kane
Plasma amine oxidase and clinical features of schizophrenia
American Journal of Psychiatry. 1985;142(8):972-973.1 -
372.
1985M. Baron; R. Gruen; J.D. Rainer; J. Kane; L. Asnis; S. Lord
American Journal of Psychiatry. 1985;142(4):447-455.99 -
373.
1985P.J. McKenna; J.M. Kane; K. Parrish
Psychotic syndromes in epilepsy
American Journal of Psychiatry. 1985;142(8):895-904.53 -
374.
1985J.T. Wegner; C.J. Rabiner; J.M. Kane
Journal of Clinical Psychology. 1985;41(6):750-752.1 -
375.
1985J.T. Wegner; F. Catalano; J. Gibraltar; J.M. Kane
Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology
Archives of General Psychiatry. 1985;42(9):860-865.31 -
376.
1985J.M. Kane; M. Woerner; J.A. Lieberman; P. Weinhold; W. Florio; M. Rubinstein; J. Rotrosen; J. Kurucz; S. Mukherjee; K. Bergmann
The prevalence of tardive dyskinesia
Psychopharmacology Bulletin. 1985;21(1):136-139.6 -
377.
1985M. Baron; R. Gruen; J. Kane; L. Asnis
Modern research criteria and the genetics of schizophrenia
American Journal of Psychiatry. 1985;142(6):697-701.3 -
378.
1985J.M. Kane
Antipsychotic drug side effects: Their relationship to dose
Journal of Clinical Psychiatry. 1985;46(5 II):16-21.8 -
379.
1985J.A. Lieberman; J.M. Kane; R. Reife
Neuromuscular effects of monoamine oxidase inhibitors
Journal of Clinical Psychopharmacology. 1985;5(4):221-228.6 -
380.
1985J.A. Lieberman; J.M. Kane; S. Sarantakos; K. Cole; A. Howard; M. Borenstein; H. Novacenko; J. Puig-Antich
Dexamethasone suppression tests in patients with obsessive-compulsive disorder
American Journal of Psychiatry. 1985;142(6):747-751.10 -
381.
1985J.M. Kane; M. Borenstein
Compliance in the long-term treatment of schizophrenia
Psychopharmacology Bulletin. 1985;21(1):23-27.37 -
382.
1985J.M. Kane
Compliance issues in outpatient treatment
Journal of Clinical Psychopharmacology. 1985;5(3 SUPPL.):22S-27S.49 -
383.
1985J.A. Lieberman; J.M. Kane; D. Gadaletta; J. Ramos-Lorenzi; K. Bergmann; J. Wegner; H. Novacenko
Methylphenidate challenge tests and course of schizophrenia
Psychopharmacology Bulletin. 1985;21(1):123-129.2 -
384.
1984Bruce J. Kinon; Daniel Merson; John M. Kane
Psychopharmacology. 1984;84(3):347-351.9 -
385.
1984Miron Baron; Rhoda Gruen; Morton Levitt; John Kane
Platelet monoamine oxidase and clinical phenomenology of schizophrenia
Psychiatry Research. 1984;11(3):205-209.0 -
386.
1984J.M. Kane; M. Woerner; P. Weinhold; J. Wegner; B. Kinon; M. Borenstein
Incidence of tardive dyskinesia: Five-year data from a prospective study
Psychopharmacology Bulletin. 1984;20(3):387-389.12 -
387.
1984J.M. Kane; J. Lieberman
Psychopharmacology Bulletin. 1984;20(2):240-249.2 -
388.
1984J.A. Lieberman; R.J. Bradley; M. Rubinstein; J.M. Kane
Antibodies to acetylcholine receptors in tardive dyskinesia
Lancet. 1984;1(8385):1066.5 -
389.
1984J.M. Kane; M. Woerner; P. Weinhold; J. Wegner; B. Kinon
Incidence of tardive dyskinesia: Five-year data from a prospective study
Psychopharmacology Bulletin. 1984;20(1):39-40.40 -
390.
1984J. Lieberman; J.M. Kane; M. Woerner; P. Weinhold
Prevalence of tardive dyskinesia in elderly samples
Psychopharmacology Bulletin. 1984;20(1):22-26.15 -
391.
1984J.A. Lieberman; J.M. Kane; D. Gadaleta; R. Brenner; M.S. Lesser; B. Kinon
Methylphenidate challenge as a predictor of relapse in schizophrenia
American Journal of Psychiatry. 1984;141(5):633-638.27 -
392.
1984J. Lieberman; J.M. Kane; M. Woerner; P. Weinhold; N. Basavaraju; J. Kurucz; K. Bergmann
Prevalence of tardive dyskinesia in elderly samples
Psychopharmacology Bulletin. 1984;20(3):382-386.11 -
393.
1984J.M. Kane
The use of depot neuroleptics: Clinical experience in the United States
Journal of Clinical Psychiatry. 1984;45(5 II):5-12.3 -
394.
1984J.M. Kane; M. Borenstein; M. Woerner
Psychopharmacologic issues in the maintenance treatment of schizophrenia
Psychopharmacology Bulletin. 1984;20(3):423-425.0 -
395.
1983J.M. Kane; M. Woerner; P. Weinhold; B. Kinon; J. Lieberman; J. Wegner
Epidemiology of tardive dyskinesia.
Clinical Neuropharmacology. 1983;6(2):109-115.3 -
396.
1983M. Baron; R. Gruen; L. Asnis; J. Kane
Age-of-onset in schizophrenia and schizotypal disorders. Clinical and genetic implications
Neuropsychobiology. 1983;10(4):199-204.2 -
397.
1983J.M. Kane
Low dose medication strategies in the maintenance treatment of schizophrenia
Schizophrenia Bulletin. 1983;9(4):528-532.3 -
398.
1983J.A. Lieberman; R. Brenner; M. Lesser; E. Coccaro; M. Borenstein; J.M. Kane
Dexamethasone suppression tests in patients with panic disorder
American Journal of Psychiatry. 1983;140(7):917-919.5 -
399.
1983J.M. Kane; K. Cole; S. Sarantakos; A. Howard; M. Borenstein
Safety and efficacy of bupropion in elderly patients: Preliminary observations
Journal of Clinical Psychiatry. 1983;44(5 II):134-136.17 -
400.
1983H.S. Green; J.M. Kane
The dexamethasone suppression test in depression
Clinical Neuropharmacology. 1983;6(1):7-24.8 -
401.
1983M. Baron; R. Gruen; L. Asnis; J. Kane
Familial relatedness of schizophrenia and schizotypal states
American Journal of Psychiatry. 1983;140(11):1437-1442.30 -
402.
1983J.M. Kane; A. Rifkin; M. Woerner; G. Reardon; S. Sarantakos; D. Schiebel; J. Ramos-Lorenzi
Low-dose neuroleptic treatment of outpatient schizophrenics I. Preliminary results for relapse rates
Archives of General Psychiatry. 1983;40(8):893-896.82 -
403.
1983J.M. Kane; F. Quitkin; A. Rifkin; J. Wegner; G. Rosenberg; M. Borenstein
Attitudinal changes on involuntarily committed patients following treatment
Archives of General Psychiatry. 1983;40(4):374-377.36 -
404.
1983J.M. Kane
Problems of compliance in the outpatient treatment of Schizophrenia
Journal of Clinical Psychiatry. 1983;44(6 II):3-6.42 -
405.
1983J.A. Lieberman; J.M. Kane
Questioning DST normalization as a guide to tricyclic discontinuation
American Journal of Psychiatry. 1983;140(2):263-264.1 -
406.
1982Miron Baron; Rhoda Gruen; Morton Levitt; John Kane
Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia
Psychiatry Research. 1982;7(2):179-187.1 -
407.
1982John M. Kane; Paul Weinhold; Bruce Kinon; James Wegner; Marcia Leader
Prevalence of abnormal involuntary movements ("spontaneous dyskinesias") in the normal elderly
Psychopharmacology. 1982;77(2):105-108.27 -
408.
1982J.M. Kane; C.J. Rabiner
Studies of maintenance pharmacotherapy in schizophrenia: the Hillside Series.
The Psychiatric hospital. 1982;13(2):47-49.0 -
409.
1982J.M. Kane
Coping with a drug-induced movement disorder: tardive dyskinesia
Geriatrics. 1982;37(12):83-87.0 -
410.
1982M. Baron; R. Gruen; M. Levitt; J. Kane
Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia
Neuropsychobiology. 1982;8(6):312-314.1 -
411.
1982H.S. Green; J.M. Kane; I. Extein
Neuroendocrine responses in diagnostic groups
Archives of General Psychiatry. 1982;39(10):1219-1220.0 -
412.
1982J.M. Kane; F.M. Quitkin; A. Rifkin; J.R. Ramos-Lorenzi; D.D. Nayak; A. Howard
Archives of General Psychiatry. 1982;39(9):1065-1069.123 -
413.
1982N.R. Schooler; J.M. Kane
Research diagnoses for tardive dyskinesia
Archives of General Psychiatry. 1982;39(4):486-487.454 -
414.
1982J.M. Kane; J.M. Smith
Tardive dyskinesia. Prevalence and risk factors, 1959 to 1979
Archives of General Psychiatry. 1982;39(4):473-481.251 -
415.
1982M. Baron; R. Gruen; L. Asnis; J. Kane
Acta Psychiatrica Scandinavica. 1982;65(4):253-262.46 -
416.
1982J.M. Kane; A. Rifkin; F. Quitkin; D. Nayak; J. Ramos-Lorenzi
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia
Archives of General Psychiatry. 1982;39(1):70-73.75 -
417.
1982J.T. Wegner; J.M. Kane
Follow-up study on the reversibility of tardive dyskinesia
American Journal of Psychiatry. 1982;139(3):368-369.7 -
418.
1982M. Baron; R. Gruen; M. Levitt; J. Kane
Neuroleptic drugs and erythrocyte catechol-O-methyltransferase in schizophrenia
Biological Psychiatry. 1982;17(11):1339-1342.0 -
419.
1982J.M. Kane; M. Woerner; P. Weinhold; J. Wegner; B. Kinon
A prospective study of tardive dyskinesia development: Preliminary results
Journal of Clinical Psychopharmacology. 1982;2(5):345-349.21 -
420.
1981John M. Kane; Thomas B. Cooper; Edward J. Sachar; Frieda S. Halpern; Samuel Bailine
Clozapine: Plasma levels and prolactin response
Psychopharmacology. 1981;73(2):184-187.60 -
421.
1981F.M. Quitkin; J. Kane; A. Rifkin; J.R. Ramos-Lorenzi; D.V. Nayak
Archives of General Psychiatry. 1981;38(8):902-907.116 -
422.
1981P. Weinhold; J.T. Wegner; J.M. Kane
Familial occurrence of tardive dyskinesia
Journal of Clinical Psychiatry. 1981;42(4):165-166.30 -
423.
1981F.M. Quitkin; J.M. Kane; A. Rifkin; J.R. Ramos-Lorenzi; K. Saraf; A. Howard; D.F. Klein
Psychopharmacology Bulletin. 1981;17(1):142-144.15 -
424.
1981J.M. Kane; F.M. Quitkin; A. Rifkin; J.R. Ramos-Lorenzi; K. Saraf; A. Howard; D.F. Klein
Prophylactic lithium with and without imipramine for bipolar I patients: A double-blind study
Psychopharmacology Bulletin. 1981;17(1):144-145.3 -
425.
1981J. Kane; F. Struve; M. Woerner; P. Weinhold
Preliminary findings with regard to risk factors in the development of tardive dyskinesia
Psychopharmacology Bulletin. 1981;17(1):47-49.1 -
426.
1980John Kane; James Wegner; Steven Stenzler; Patricia Ramsey
The prevalence of presumed tardive dyskinesia in psychiatric inpatients and outpatients
Psychopharmacology. 1980;69(3):247-251.1 -
427.
1980J.M. Kane; N.R. Schooler
Tardive dyskinesia workgroup report.
Psychopharmacology Bulletin. 1980;16(3):35-36.1 -
428.
1980Frederic M. Quitkin; Arthur Rifkin; Ming T. Tsuang; John M. Kane; Donald F. Klein
Psychiatry Research. 1980;2(1):99-105.1 -
429.
1980J. Kane; F.A. Struve; P. Weinhold; M. Woerner
Strategy for the study of patients at high risk for tardive dyskinesia
American Journal of Psychiatry. 1980;137(10):1265-1267.4 -
430.
198061 -
431.
1980A. Rifkin; K. Saraf; J. Kane; D. Ross; D.F. Klein
A comparison of trimipramine and imipramine: A controlled study
Journal of Clinical Psychiatry. 1980;41(4):124-129.0 -
432.
1979John M. Kane; Arthur Rifkin; Frederic Quitkin; Devdutt Nayak; Kishore Saraf; Jorge R. Ramos-Lorenzi; Donald F. Klein; Edward J. Sachar
Low dose fluphenazine decanoate in maintenance treatment of schizophrenia
Psychiatry Research. 1979;1(3):341-348.3 -
433.
1979J. Kane; A. Rifkin; F. Quitkin
A pilot study of 'low-dose' fluphenazine decanoate in outpatient schizophrenics
Psychopharmacology Bulletin. 1979;15(2):78-80.1 -
434.
1979A. Rifkin; F. Quitkin; J. Kane; D.F. Klein; D. Ross
The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics
Biological Psychiatry. 1979;14(3):499-508.1 -
435.
1979F.A. Struve; J.M. Kane; J.T. Wegner; J. Kantor
Clinical EEG Electroencephalography. 1979;10(3):151-163.0 -
436.
1979J.T. Wegner; F.A. Struve; J.S. Kantor; J.M. Kane
Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study
Archives of General Psychiatry. 1979;36(5):599-603.2 -
437.
1979F. Quitkin; A. Rifkin; J. Kane
Psychopharmacology Bulletin. 1979;15(2):35-39.0 -
438.
1978F. Quitkin; A. Rifkin; J. Kane; J.R. Ramos-Lorenzi; D.F. Klein
American Journal of Psychiatry. 1978;135(5):570-572.21 -
439.
1978J. Kane; J. Wegner; F. Struve
The mitten pattern as a potential EEG predictor of tardive dyskinesia
Psychopharmacology Bulletin. 1978;14(2):35-36.0 -
440.
1978J. Kane; F. Quitkin; A. Rifkin; D.F. Klein
American Journal of Psychiatry. 1978;135(12):1539-1542.2 -
441.
1978F. Quitkin; A. Rifkin; J. Kane; J.R. Ramos-Lorenzi; D.F. Klein
Archives of General Psychiatry. 1978;35(7):889-892.10 -
442.
1978J. Kane; A. Rifkin; F. Quitkin; D.F. Klein
Extrapyramidal side effects with lithium treatment
American Journal of Psychiatry. 1978;135(7):851-853.15 -
443.
1978A. Rifkin; F. Quitkin; J. Kane; F. Struve; D.F. Klein
Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal
Archives of General Psychiatry. 1978;35(4):483-489.18 -
444.
1977J.T. Wegner; F.A. Struve; J.M. Kane
The B-mitten EEG pattern and tardive dyskinesia: a possible association.
American Journal of Psychiatry. 1977;134(10):1143-1145.0 -
445.
1977J.M. Kane
Improvement or relief from side effects.
American Journal of Psychiatry. 1977;134(7):819-820.0 -
446.
1977A. Rifkin; F. Quitkin; J. Kane; D.F. Klein
Psychopharmacology Bulletin. 1977;13(2):49-50.1
